|August 19, 2020
|Predicting Response and Improving Efficacy of CAR T-cell Therapy in DLBCL
|The University of Texas M.D. Anderson Cancer Center
|Principal Investigator/Program Director
CD19 CAR T-cell therapy has been a major breakthrough and is the last chance of a cure for many relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients. Despite the success, over 50% of patients fail to respond or relapse following an initial response. Identifying patients that are likely to fail such a therapy is an important challenge, and could potentially allow for the consolidation with additional therapy following CAR T infusion to improve its efficacy. In addition, elucidating the mechanisms of primary resistance/relapse will help develop novel combinational strategies targeting the resistance mechanisms to improve its efficacy. We have found that monitoring tumor mutations...